ATG7 (Ubiquitin-like modifier-activating enzyme ATG7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma and Clear cell renal cell carcinoma. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
E1-like activating enzyme involved in the 2 ubiquitin-like systems required for cytoplasm to vacuole transport (Cvt) and autophagy. Activates ATG12 for its conjugation with ATG5 as well as the ATG8 family proteins for their conjugation with phosphatidylethanolamine. Both systems are needed for the ATG8 association to Cvt vesicles and autophagosomes membranes. Required for autophagic death induced by caspase-8 inhibition. Facilitates LC3-I lipidation with phosphatidylethanolamine to form LC3-II which is found on autophagosomal membranes. Required for mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the mitochondria to a basal level to fulfill cellular energy requirements and preventing excess ROS production. Location: Cytoplasm; Preautophagosomal structure (UniProt). Locus 3p25.3 (HGNC).
- Pancreatic ductal adenocarcinoma: CIViC evidence names this disease
- Renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC)
- Clear cell renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"ATG7" OR ABSTRACT:"ATG7" OR TITLE:"autophagy related 7" OR ABSTRACT:"autophagy related 7" OR TITLE:"Ubiquitin-like modifier-activating enzyme ATG7" OR ABSTRACT:"Ubiquitin-like modifier-activating enzyme ATG7" OR TITLE:"GSA7" OR ABSTRACT:"GSA7" OR TITLE:"DKFZp434N0735" OR ABSTRACT:"DKFZp434N0735" OR TITLE:"APG7L" OR ABSTRACT:"APG7L") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ATG7, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/atg7.json. Licence CC BY-NC 4.0.